全球肺纖維化生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球肺纖維化生物標記市場預計將從2025年的49.5億美元成長至2034年的76.1億美元，2026年至2034年的複合年成長率（CAGR）為4.89%。該市場正經歷顯著成長，主要受肺纖維化盛行率上升以及對早期精準診斷需求的推動。生物標記在識別疾病進展、監測治療效果和改善患者預後方面發揮著至關重要的作用。人們對個人化醫療和標靶治療日益成長的興趣也顯著促進了該市場的擴張。分子生物學和診斷技術的進步正在推動新生物標記的發現，進一步促進了市場成長。

關鍵促進因素包括健康意識的提高、研發投入的增加以及診斷技術的進步。醫療機構擴大採用基於生物標記的檢測方法，以提高診斷準確性並減少治療延誤。臨床檢測的擴展以及研究機構和製藥公司之間的合作正在加速新型生物標記的開發。此外，人口老化也加劇了肺部疾病的發生率。

由於生物標記發現和檢驗的持續創新，市場前景依然十分光明。人工智慧 (AI) 和數據分析的融合將提升診斷能力，並實現更精準的治療方案製定。隨著醫療基礎設施的不斷完善，新興市場有望迎來顯著的成長機會。隨著早期診斷和個人化治療的日益普及，肺纖維化生物標記市場預計將持續擴張。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含多個關鍵組成部分，旨在幫助您全面了解市場環境。

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局概述。

市場動態：對影響市場成長的關鍵促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。本部分深入分析了競爭趨勢以及主要參與者所採取的策略，提供了寶貴的見解。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新的投資機會。本部分重點在於潛在的成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球肺纖維化生物標記市場：依檢測類型分類

• 市場分析、洞察與預測
• 驗血
• 肺功能測試
• 影像檢查
• 切片檢查
• 其他測試類型

第5章：全球肺纖維化生物標記市場：依適應症分類

• 市場分析、洞察與預測
• 特發性肺纖維化（IPF）
• 類風濕性關節炎的間質性肺病（RA-ILD）

估價與預測：按地區分類

• 藥物引起的肺纖維化
• 新冠肺炎相關肺纖維化
• 塵肺
• 類肉瘤病
• 其他跡象

第6章 全球肺纖維化生物標記市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 專科診所
• 診斷實驗室
• 研究和學術機構
• 其他

第7章 全球肺纖維化生物標記市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和分銷通路合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Biocartis NV
  • Biogen Inc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Lung Therapeutics Inc
  • Myriad Genetics Inc
  • OptiKira LLC
  • Respivant Sciences GmbH
  • Veracyte Inc

The global pulmonary fibrosis biomarkers market size is expected to reach USD 7.61 Billion in 2034 from USD 4.95 Billion in 2025, growing at a CAGR of 4.89 during 2026-2034.This market is experiencing significant growth driven by the increasing prevalence of pulmonary fibrosis and the need for early and accurate diagnosis. Biomarkers play a crucial role in identifying disease progression, monitoring treatment response, and improving patient outcomes. The growing focus on personalized medicine and targeted therapies is significantly contributing to the expansion of this market. Advances in molecular biology and diagnostic technologies are enabling the discovery of new biomarkers, further supporting market growth.

Key drivers include rising healthcare awareness, increasing investments in research and development, and advancements in diagnostic techniques. Healthcare providers are increasingly adopting biomarker-based tests to improve diagnostic accuracy and reduce treatment delays. The expansion of clinical trials and collaborations between research institutions and pharmaceutical companies are accelerating the development of novel biomarkers. Additionally, the growing aging population is contributing to the rising incidence of pulmonary diseases.

Future prospects for this market remain highly promising, with continuous innovation in biomarker discovery and validation. The integration of artificial intelligence and data analytics will enhance diagnostic capabilities and enable more precise treatment planning. Emerging markets are expected to offer significant growth opportunities due to improving healthcare infrastructure. As the focus on early diagnosis and personalized treatment continues to grow, the pulmonary fibrosis biomarkers market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Test Type

• Blood Test
• Pulmonary Function Test
• Imaging Test
• Lung Biopsy
• Other Test Types

By Indication

• Idiopathic Pulmonary Fibrosis (IPF)
• Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)
• Drug-Induced Pulmonary Fibrosis
• COVID-19-Related Pulmonary Fibrosis
• Pneumoconiosis
• Sarcoidosis
• Other Indications

By End-user

• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Other End-Users

COMPANIES PROFILED

• Biocartis NV, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Galapagos NV, Lung Therapeutics Inc., Myriad Genetics Inc., OptiKira LLC, Respivant Sciences GmbH, Veracyte Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Blood Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pulmonary Function Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Imaging Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Lung Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Test Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Idiopathic Pulmonary Fibrosis (IPF) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)

Estimates and Forecasts By Regions 2022-2034 (USD MN)

• 5.4. Drug-Induced Pulmonary Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. COVID-19-Related Pulmonary Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Pneumoconiosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Sarcoidosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Research & Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Type
  • 7.2.2 By Indication
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Type
  • 7.3.2 By Indication
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Type
  • 7.4.2 By Indication
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Type
  • 7.5.2 By Indication
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Type
  • 7.6.2 By Indication
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PULMONARY FIBROSIS BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Biocartis NV
  • 9.2.2 Biogen Inc
  • 9.2.3 Bristol-Myers Squibb Company
  • 9.2.4 F. Hoffmann-La Roche Ltd
  • 9.2.5 Galapagos NV
  • 9.2.6 Lung Therapeutics Inc
  • 9.2.7 Myriad Genetics Inc
  • 9.2.8 OptiKira LLC
  • 9.2.9 Respivant Sciences GmbH
  • 9.2.10 Veracyte Inc